Form 4: Solen Therapeutics CEO Sells Shares to Cover Tax Obligations

Solen Therapeutics CEO, Anish Bhatnagar, sold shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Anish Bhatnagar, CEO of Soleno Therapeutics, sold a total of 21,091 shares of common stock across three transactions.
• The sales occurred on January 2nd and 3rd, 2025.
• The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The weighted average sale prices ranged from $45.3656 to $46.1764 per share.
• Following these transactions, Mr. Bhatnagar still beneficially owns 698,462 shares of common stock, some of which are RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Risks

• The sale of shares by a company's CEO could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• The reported transactions are consistent with standard procedures for managing stock-based compensation.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on shareholder sentiment.

Key Dates

Keywords

Solen Therapeutics, Anish Bhatnagar, stock sale, restricted stock units, tax obligations, insider trading, SEC Form 4